Skip to content
Disclosery

Propel Bio Management, LLC

Follow

13F filer, CIK 1969764, Los Angeles, CA

Propel Bio Management, LLC reported $86,073,350 across 18 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-15. Its ten largest share positions make up 91.73% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000898432-25-000357

Period
2025-03-31
Reported value
$86.1M
Holdings
18
Top 10 weight
91.73%
New
2
Sold out
5

Largest buys vs the previous quarter

SecurityShares changeApprox. value
DCTHadded+160,600$2.04M
MISTnew+1,451,557$1.16M
MAAT PHARMA SACAadded+163,272$1.02M
PHATadded+145,000$909K
Applied Therapeutics Incadded+1,670,000$816K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ARDXexited-950,947-$4.82M
AKROreduced-114,845-$4.65M
MDGLreduced-13,000-$4.31M
KYMRexited-56,359-$2.27M
KURAexited-130,000-$1.13M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0000898432-25-000357, largest first. % of portfolio is the value over $86,073,350, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PAGPPLAINS GP HLDGS L PQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,272,360 shares; 2024Q4: 1,272,360 shares; 2025Q1: 1,272,360 shares 1,272,360$27.2M31.57%0Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 43,032 shares; 2024Q4: 43,032 shares; 2025Q1: 30,032 shares 30,032$9.95M11.56%-13,000Timeline
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 343,729 shares; 2024Q4: 343,729 shares; 2025Q1: 228,884 shares 228,884$9.27M10.76%-114,845Timeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 869,927 shares; 2024Q4: 989,927 shares; 2025Q1: 1,134,927 shares 1,134,927$7.12M8.27%+145,000Timeline
ACHVACHIEVE LIFE SCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,453,092 shares; 2024Q4: 2,453,092 shares; 2025Q1: 2,453,092 shares 2,453,092$6.55M7.61%0Timeline
Applied Therapeutics IncApplied Therapeutics IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,567,858 shares; 2024Q4: 9,615,420 shares; 2025Q1: 11,285,420 shares 11,285,420$5.52M6.41%+1,670,000
RNAMAVIDITY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 178,500 shares; 2024Q4: 178,500 shares; 2025Q1: 178,500 shares 178,500$5.27M6.12%0Timeline
ABEOABEONA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 624,022 shares; 2024Q4: 624,022 shares; 2025Q1: 624,022 shares 624,022$2.97M3.45%0Timeline
TCRXTSCAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,087,139 shares; 2024Q4: 2,087,139 shares; 2025Q1: 2,087,139 shares 2,087,139$2.88M3.35%0Timeline
DCTHDELCATH SYS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 17,000 shares; 2025Q1: 177,600 shares 177,600$2.26M2.63%+160,600Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 133,259 shares; 2024Q4: 183,259 shares; 2025Q1: 183,259 shares 183,259$2.25M2.62%0Timeline
ZVRAZEVRA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 179,874 shares; 2024Q4: 179,874 shares; 2025Q1: 179,874 shares 179,874$1.35M1.57%0Timeline
MISTMILESTONE PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,451,557 shares 1,451,557$1.16M1.35%newTimeline
MAAT PHARMA SACAMAAT PHARMA SACAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,397 shares; 2024Q4: 3,151 shares; 2025Q1: 166,423 shares 166,423$1.04M1.21%+163,272
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 228,317 shares 228,317$434K0.5%newTimeline
ATHIRA PHARMA INCATHIRA PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,492,792 shares; 2024Q4: 1,492,792 shares; 2025Q1: 1,492,792 shares 1,492,792$425K0.49%0
EIGRQEIGER BIOPHARMACEUTICALSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 146,381 shares; 2024Q4: 146,381 shares; 2025Q1: 146,381 shares 146,381$423K0.49%0Timeline
CHINOOK THERAPEUTICS CVRCHINOOK THERAPEUTICS CVRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 79,357 shares; 2024Q4: 79,357 shares; 2025Q1: 79,357 shares 79,357$38.5K0.04%0

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ARDXARDELYX INC950,947$4.82Mshares
KYMRKYMERA THERAPEUTICS INC56,359$2.27Mshares
KURAKURA ONCOLOGY INC130,000$1.13Mshares
JSPRJASPER THERAPEUTICS INC20,000$428Kshares
CMPSCOMPASS PATHWAYS PLC25,209$95.3Kshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000898432-25-000357 base2025-05-15acceptance time not in the bulk data set